EDIT · Editas Medicine
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $2.75
Note written ·
How this view changed
- · Rating cut from Medium to Low. Guidance, 9 November 2026: Editas's third-quarter 2026 release guided initial safety and tolerability data for the first quarter of 2027 and topline Part 1 safety and efficacy results for the second half of 2027, with first patient dosing still guided only for 2026.
Price against the kill line
21.1% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $2.75, set on 12 November 2026. The shares are down 23.6% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $2.75, the 9 November 2026 close before the post-results decline, which would show the shares leading again. Company-reported human LDL-C lowering ahead of the second-half 2027 guide would also point to the shares leading.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 9 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 10.4
- Revenue, change on a year (%)
- +37.4
- Operating margin (%)
- −234.3
- Free cash flow, four quarters ($M)
- −111
- Net cash, cash less debt ($M)
- 133
- Enterprise value to sales (×)
- 4.0
- Free-cash-flow yield (%)
- −33.0
All filed numbers
What Editas Medicine reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Operating margin (%) |
|---|---|---|---|
| first filed | 10.4 | +37.4 | −234.3 |
| first filed | 11.9 | +232.3 | −156.0 |
| first filed | 2.8 | −39.2 | −883.2 |
| first filed | 24.7 | −19.2 | −31.3 |
| first filed | 7.5 | +12265.6 | −325.4 |
| first filed | 3.6 | +597.5 | −1440.6 |
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: −72.2 | −23.4 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +70.5 |
| Operating cash flow ($M) | −110 |
| Capital spending ($M) | 0.3 |
| Free cash flow ($M) | −111 |
| Cash and short-term investments ($M) | 190 |
| Debt ($M) non-current long-term debt plus current maturities | 56.8 |
| Net cash, cash less debt ($M) | 133 |
| Deferred revenue ($M) −33.0% on a year | 36.3 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 7.7 |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 84.5 |
| Market value ($M) | 335 |
| Enterprise value, market value plus net debt ($M) | 202 |
| Enterprise value to sales (×) | 4.0 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 4.0 |
| Free-cash-flow yield (%) | −33.0 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 24.7% of shares outstanding sold short, 14.3 days of average trading to cover, +2.9% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $89K |
| 12 monthsfrom | $0 | $177K |
The thesis
Editas Medicine's shares look more likely to lag the S&P 500 than lead it over the next three months. The company's 9 November 2026 third-quarter release guided human efficacy data for the second half of 2027, so the only human items inside the window are a first patient dosed and early safety and tolerability data guided for the first quarter of 2027.
The shares closed at $2.38 on 11 November 2026, 39.6% below the 52-week intraday high of $3.94 set on 27 May 2026. They sit under both the 50-day average of $2.67 and the 200-day average of $2.70, and the three-month price change is −15.3%. Whether the first patient is dosed by year-end, and what the first-quarter 2027 safety update shows, settle the near-term read.
Editas's EDIT-401 is a one-time gene-editing treatment aimed at heterozygous familial hypercholesterolemia, an inherited condition that raises LDL ("bad") cholesterol. The Phase 1/2 Strive trial won approval in Australia on 8 October 2026. The 9 November 2026 release said the company "remains on track to begin patient dosing this year", which means no patient had been dosed at the report date.
Bullish and bearish views on Editas Medicine, Inc.
The bull case on Editas Medicine, Inc. (EDIT), in brief: cash funds the programme. The bear case: efficacy data sit outside the window.
Bull case
- Cash funds the programme. Editas reported $190.2 million in cash, cash equivalents and marketable securities at 30 September 2026, against $146.6 million at 31 December 2025, and guided its runway into the second half of 2028 (company release, 9 November 2026).
- Primate effect lasts. Editas presented EDIT-401 data at the American Heart Association Scientific Sessions in early November 2026. LDL-C reduction of 90% or more was maintained over 10 months in non-human primates, per the company's 9 November 2026 release.
- Quarterly results beat estimates. Third-quarter revenue was $10.4 million against $7.5 million a year earlier, and the net loss was $23.4 million, or $0.15 a share, against $25.1 million, or $0.28, a year earlier. Benzinga reported on 9 November 2026 that revenue beat the $4.46 million estimate and the loss beat the $0.18 estimate.
- Analysts stay positive. A 11 November 2026 report said Wells Fargo and H.C. Wainwright maintained Buy ratings after the third-quarter report.
Bear case
- Efficacy data sit outside the window. The 9 November 2026 release guided only initial safety and tolerability data for the first quarter of 2027. Topline Part 1 safety and efficacy results are guided for the second half of 2027.
- Dosing has not started. The company guided first patient dosing only as "this year" on 9 November 2026, with no date and four sites across Australia and New Zealand. New Zealand review had been submitted as of 8 October 2026.
- The shares fell after the report. They closed at $2.75 on 9 November 2026, $2.50 on 10 November 2026 and $2.38 on 11 November 2026. The 8 October 2026 trial-clearance gain has been given back.
- Dilution is built into the share count. The weighted-average share count was about 153.6 million in the third quarter of 2026, against about 90.1 million a year earlier, per the company release. A Form S-3 filed on 31 August 2026 registers up to $400 million of mixed securities.
- Operating costs are rising. Research and development expense was $21.2 million against $19.8 million a year earlier, and general and administrative expense was $13.5 million against $12.3 million, per the 9 November 2026 release.
Price setup
The close of $2.38 on 11 November 2026 is below the 50-day average of $2.67 and the 200-day average of $2.70, both adjusted daily-close measures as of that session. The shares were above both averages on 9 November 2026 at $2.75, then lost that ground in two sessions. The 52-week closing low is $1.67 on 5 February 2026.
Insider filings show no open-market sales in recent weeks. SEC Form 4 filings dated 6 November 2026 report share awards on 5 November 2026 to Chief Executive Officer Gilmore Neil O'Neill (43,567 shares) and Chief Scientific Officer Linda Burkly (16,533 shares). The last open-market sales in the filings were small, under Rule 10b5-1 plans, at $3.04 on 3 September 2026.
Catalysts ahead
- 31 December 2026: Guided deadline for first patient dosing in the Strive trial. The company said on 9 November 2026 it is on track to begin dosing this year; a miss would push the first human data further out.
- 31 March 2027 (est.): End of the guided first-quarter 2027 window for initial EDIT-401 safety and tolerability data. This is the first human data point, and it covers safety rather than cholesterol lowering.
- 31 December 2027 (est.): End of the guided second-half 2027 window for topline Part 1 safety and efficacy results. These results show whether the primate LDL-C reduction carries over to patients; they fall after the three-month window.
What would change the view
A daily close above $2.75, the 9 November 2026 close before the post-results decline, which would show the shares leading again. Company-reported human LDL-C lowering ahead of the second-half 2027 guide would also point to the shares leading.
What it trades with
Editas trades with small-capitalisation gene-editing and clinical-stage biotech shares. Its price follows company trial news and financing more than earnings, because it has no product revenue. Third-quarter revenue came largely from collaboration accounting, so the report's revenue beat carried little information for the shares.
The evidence, claim by claim (7)
- Editas reported $190.2 million in cash, cash equivalents and marketable securities at 30 September 2026, with runway guided into the second half of 2028. Editas Medicine third-quarter 2026 results release, 9 November 2026 · as of
- Editas guided initial EDIT-401 safety and tolerability data for the first quarter of 2027 and topline Part 1 safety and efficacy results for the second half of 2027; it remains on track to begin patient dosing in 2026. Editas Medicine third-quarter 2026 results release, 9 November 2026 · as of
- Third-quarter 2026 revenue was $10.4 million, research and development expense $21.2 million, general and administrative expense $13.5 million, and net loss $23.4 million, or $0.15 a share. Editas Medicine third-quarter 2026 results release, 9 November 2026 · as of
- LDL-C reduction of 90% or more with EDIT-401 was maintained over 10 months in non-human primates, presented at the American Heart Association Scientific Sessions 2026. Editas Medicine third-quarter 2026 results release, 9 November 2026 · as of
- Editas announced approval to start the Phase 1/2 Strive trial of EDIT-401 in heterozygous familial hypercholesterolemia in Australia, with New Zealand review submitted. Editas Medicine announcement, 8 October 2026 · as of
- Weighted-average shares outstanding were about 153.6 million in the third quarter of 2026, against about 90.1 million a year earlier. Editas Medicine third-quarter 2026 results release, 9 November 2026 · as of
- Editas filed a Form S-3 registering up to $400 million of mixed securities. Benzinga, 31 August 2026 · as of
Sources
Related · shared themes
MRK
Merck
Merck's newer drugs and under-the-skin Keytruda are carrying its growth after raised 2026 guidance on 29 October 2026; the early-February…
MRNA
Moderna
Moderna's shares are more likely to lag the S&P 500 over three months: a 246.5% three-month gain already prices its surprise profit and…
BMY
Bristol-Myers Squibb
Bristol Myers Squibb raised 2026 revenue guidance to $49.75–$50.25 billion on 29 October 2026 but cut adjusted EPS guidance to $6.35–$6.55…
EWTX
Edgewise Therapeutics
Edgewise Therapeutics is modestly more likely than not to beat the S&P 500 over three months: FDA-cleared Phase 3 plans for heart drug…